White cell disorders non neoplastic

Cheru Beyene, MD
DMU
October 2016

INTRODUCTION

- THINK- PAIR- SHARE
 - DESCRIBE DEVELOPMENT OF HEMATOLOGIC
 SYSTEM
 - LIST DOWN HEAMATOLOGIC CELLS
 - Sites of haematopoesis during different developmental stages

Normal values

Leukocytes			
Alkaline phosphatase (LAP)	WB	0.2-1.6 µkat/L	13-100 µ/L
Count (WBC)	WB	3.54-9.06×10 ⁹ /L	3.54-9.06×10 ³ /mm ³
Mean corpuscular hemoglobin (MCH)	WB	26.7-31.9 pg/cell	26.7-31.9 pg/cell
Mean corpuscular hemoglobin concentration (MCHC)	WB	323-359 g/L	32.3-35.9 g/dL
Mean corpuscular hemoglobin of reticulocytes (CH)	WB	24-36 pg	24-36 pg
Mean corpuscular volume (MCV)	WB	79–93.3 fL	79–93.3 μm³
Mean platelet volume (MPV)	WB	9.00-12.95 fL	9.00-12.95
Osmotic fragility of erythrocytes	WB		
Direct		0.0035-0.0045	0.35-0.45%
Indirect		0.0030-0.0065	0.30-0.65%
Partial thromboplastin time, activated	Р	26.3-39.4 s	26.3-39.4 s
Plasminogen	р		
Antigen		84-140 mg/L	8.4-14.0 mg/dL
Functional		0.70-1.30	70-130%
Plasminogen activator inhibitor 1	Р	4-43 µg/L	4-43 ng/mL
Platelet aggregation	PRP	Not applicable	>65% aggregation in collagen, ristocetin, a
Platelet count	WB	165-415×10 ⁹ /L	165-415×10 ³ /mm ³

Normal values

TABLE 13-1 -- Adult Reference Ranges for Blood Cells

Cell Type	
White cells (× 103/µL)	4.8-10.8
Granulocytes (%)	40-70
Neutrophils (× 10 3/µL)	1.4-6.5
Lymphocytes (× 10 3/µL)	1.2-3.4
Monocytes (× 103/µL)	0.1-0.6
Eosinophils (× 103/µL)	0-0.5
Basophils (× 10 ₃/µL)	0-0.2
Red cells (× 10 3/µL)	4.3-5, men; 3.5-5.0, women
Platelets (× 10 ₃/µL)	150-450

Pediatric CBC

ANALYTE OR PROCEDURE	SPECIMEN	REFERENC	E VALUES (USA)	CONVERSION FACTOR	REFERENCE VALUES (SI)	COMMENTS
COMPLETE BLOOD COUNT						
Hematocrit (HCT, Hct)	W(E)		% of packed red cells (V red cells/V whole blood cells ? 100		Volume fraction (V red cells/V whole blood)	
		0-30 days	44-70%	?0.01	0.44-0.70	
		1-23 mo	32-42%		0.32-0.42	
Calculated from mean corpuscular volume (MCV) and RBC count (electronic displacement or laser)		2-9 yr	33-43%		0.33-0.43	
		10-17 yr M	36-47%		0.36-0.47	
		F	35-45%		0.35-0.45	
		>18-99 yr M	42-52%		0.42-0.52	
		F	37-47%		0.37-0.47	
Hemoglobin (Hb)	W(E)		g/dL		mmol/L	
		0-30 days	15.0-24.0	?0.155	2.32-3.72	MW Hb = 64,500
		1-23 mo	10.5-14.0		1.63-2.17	
		2-9 yr	11.5-14.5		1.78-2.25	
		10-17 yr M	12.5-16.1		1.93-2.50	
		F	12.0-15.0		1.86-2.32	
		>18-99 yr M	13.5-18.0		2.09-2.79	
		F	12.5-16.0		1.93-2.48	
	P(H)	See Chemical	l Elements			

Erythrocyte indices (RBC indices)					
Mean corpuscular hemoglobin (MCH)	W(E)		pg/cell		fmol/cell
		0-30 days	33-39	?0.0155	0.51-0.60
		1-23 mo	24-30		0.37-0.46
		2-9 yr	25-31		0.39-0.48
		10-17 yr M	26-32		0.26-0.32
		F	26-32		0.26-0.32
		>18-99 yr M	27-31		0.27-0.31
		F	27-31		0.27-0.31
Mean corpuscular hemoglobin	W(E)		% Hb/cell or g Hb/dL RBC		mmol Hb/L RBC
concentration (MCHC)			32-36	?0.155	4.96-5.58
Mean corpuscular volume (MCV)	W(E)		<u>?m³</u>		<u>fL</u>
		0-30 days	99-115	?1	99-115
		1-23 mo	72-88		72-88
		2-9 yr	76-90		76-90
		10-17 yr	78-95		78-95
		>18-99 yr	78-100		78-100
Leukocyte count (WBC count)	W(E)	?1,000 cells/mm ³ (?L)			210 ⁹ cells/L
		0-30 days	9.1-34.0	?1	9.1-34.0
		1-23 mo	6.0-14.0		6.0-14.0
		2-9 yr	4.0-12.0		45.0-12.0
		10-17 yr	4.0-10.5		4.0-10.5
		18-99 yr	4.0-10.5		4.0-10.5

Leukocyte differential	W(E)	<u>%</u>		Number fraction
Myelocytes		0%	?0.01	0
Neutrophils ("bands")		3-5%		0.03-0.05
Neutrophils ("segs")		54-62%		0.54-0.62
Lymphocytes		25-33%		0.25-0.33
Monocytes		3-7%		0.03-0.07
Eosinophils		1-3%		0.01-0.03
Basophils		0-0.75%		0-0.0075
		Cells/mm ³ (?L)		?10 ⁶ cells/L
Myelocytes		0	?1	0
Neutrophils ("bands")		150-400		150-400
Neutrophils ("segs")		3,000-5,800		3,000-5,800
Lymphocytes		1,500-3,000		1,500-3,000
Monocytes		285-500		285-500
Eosinophils		50-250		50-250
Basophils		15-50		15-50
	W(E)	<u>?10 ³/mm ³ (?L)</u>		<u>?10</u> ⁹ <u>/L</u>
Platelet count (thrombocyte count)		Newborn 84-478 (after 1 wk, same as adult)	?10°	84-478
		Adult 150-400		150-400

- Disorders of white blood cells can be classified into two broad categories:
- proliferative disorders, in which there is an expansion of leukocytes
 - reactive
 - neoplastic
- *leukopenias*, which are defined as a deficiency of leukocytes.

Leukopenia

- An abnormally low white cell count (*leukopenia*) usually results from reduced numbers of
 - Neutrophils (neutropenia, granulocytopenia).
 - Lymphopenia is less common; most commonly observed in advanced human immunodeficiency virus (HIV) infection, therapy with glucocorticoids or cytotoxic drugs, autoimmune disorders, malnutrition, and certain acute viral infections.

NEUTROPENIA, AGRANULOCYTOSIS

- *Neutropenia*, a reduction in the number of neutrophils in the blood, occurs in a wide variety of circumstances.
- Agranulocytosis, a clinically significant reduction in neutrophils, has the serious consequence of making individuals susceptible to bacterial and fungal infections.

Pathogenesis

- A reduction in circulating granulocytes occurs if there is:
- (1) inadequate or ineffective granulopoiesis,
- (2) accelerated removal of neutrophils from the blood.

- *Inadequate or ineffective granulopoiesis* is observed in the setting of
 - Suppression of hematopoietic stem cells, as occurs in aplastic anemia and a variety of infiltrative marrow disorders (tumors, granulomatous disease, etc.);
 - Suppression of committed granulocytic precursors by exposure to certain drugs
 - Disease states associated with *ineffective hematopoiesis*, such as megaloblastic anemias and myelodysplastic syndromes, where defective precursors die in the marrow
 - Rare congenital conditions (such as Kostmann syndrome) in which inherited defects in specific genes impair granulocytic differentiation

- Accelerated removal or destruction of neutrophils occurs with
 - *Immunologically mediated injury* to neutrophils, which can be idiopathic, associated with a well-defined immunological disorder (e.g., systemic lupus erythematosus), or caused by exposure to drugs
 - Splenomegaly, in which splenic sequestration of neutrophils leads to excessive destruction.
 - Increased peripheral utilization, which can occur in overwhelming bacterial, fungal, or rickettsial infections

- The most common cause of agranulocytosis is drug toxicity.
- Certain drugs, such as alkylating agents and antimetabolites used in cancer treatment, produce agranulocytosis in a predictable, doserelated fashion.
- Because such drugs cause a generalized suppression of the bone marrow, production of red cells and platelets is also affected.

- Agranulocytosis can also occur as an idiosyncratic reaction to a large variety of agents.
 - The roster of implicated drugs includes aminopyrine, chloramphenicol, sulfonamides, chlorpromazine, thiouracil, and phenylbutazone.
 - The neutropenia induced by chlorpromazine and related phenothiazines results from a toxic effect on granulocytic precursors in the bone marrow.

Morphology.

- The alterations in the bone marrow vary with cause. With excessive destruction of neutrophils in the periphery, the marrow is usually hypercellular due to a compensatory increase in granulocytic precursors. Hypercellularity is also the rule with neutropenias caused by ineffective granulopoiesis, as occurs in megaloblastic anemias and myelodysplastic syndromes.
- Agranulocytosis caused by agents that suppress or destroy granulocytic precursors is understandably associated with marrow hypocellularity.

- Infections are a common consequence of agranulocytosis.
- Ulcerating necrotizing lesions of the gingiva, floor of the mouth, buccal mucosa, pharynx, or elsewhere in the oral cavity (agranulocytic angina) are quite characteristic.
- These are typically deep, undermined, and covered by gray to green-black necrotic membranes from which numerous bacteria or fungi can be isolated.

- Clinical Features.
 - The symptoms and signs of neutropenia are related to infection, and include malaise, chills, and fever, often followed by marked weakness and fatigability.
 - Serious infections are most likely when the neutrophil count falls below 500 per mm³.
 - Because infections are often fulminant, broad-spectrum antibiotics must be given expeditiously whenever signs or symptoms appear.
 - In some instances, such as following myelosuppressive chemotherapy, neutropenia is treated with G-CSF, a growth factor that stimulates the production of granulocytes from marrow precursors

- Reactive (Inflammatory) Proliferations of White Cells and Lymph Nodes
 - Leukocytosis refers to an increase in the number of white cells in the blood. It is a common reaction to a variety of inflammatory states.

- Pathogenesis.
- The peripheral blood leukocyte count is influenced by several factors,
 - The size of the myeloid and lymphoid precursor and storage cell pools in the bone marrow, thymus, circulation, and peripheral tissues
 - The rate of release of cells from the storage pools into the circulation
 - The proportion of cells that are adherent to blood vessel walls at any time (the marginal pool)
 - The rate of extravasation of cells from the blood into tissues

INCREASED PRODUCTION IN THE MARROW

Chronic infection or inflammation (growth factor-dependent)

Paraneoplastic (e.g., Hodgkin lymphoma; growth factor-dependent)

Myeloproliferative disorders (e.g., chronic myeloid leukemia; growth factorindependent)

INCREASED RELEASE FROM MARROW STORES

Endotoxemia

Infection

Hypoxia

DECREASED MARGINATION

Exercise

Catecholamines

DECREASED EXTRAVASATION INTO TISSUES

Glucocorticoids


- Acute infection there is a rapid increase in the egress of mature granulocytes from the bone marrow pool.
- If the infection is prolonged, the release of interleukin-1 (IL-1), tumor necrosis factor (TNF), and other inflammatory cytokines stimulates bone marrow stromal cells and T cells to produce increased amounts of hematopoietic growth factors, which enhance the proliferation and differentiation of committed granulocytic progenitors and, over several days, cause a sustained increase in neutrophil production.

Causes

- Neutrophilic leukocytosis
 - Acute bacterial infections, especially those caused by pyogenic organisms; sterile inflammation caused by, for example, tissue necrosis (myocardial infarction, burns)
- Eosinophilic leukocytosis (eosinophilia)
 - Allergic disorders such as asthma, hay fever; certain skin diseases (e.g., pemphigus, dermatitis herpetiformis);
 parasitic infestations; drug reactions; certain malignancies (e.g., Hodgkin and some non-Hodgkin lymphomas);
 collagen vascular disorders and some vasculitides; atheroembolic disease (transient)

- Basophilic leukocytosis (basophilia) Rare,
 - often indicative of a myeloproliferative disease (e.g., chronic myeloid leukemia)
- Monocytosis
 - Chronic infections (e.g., **tuberculosis**), bacterial endocarditis, rickettsiosis, and malaria; collagen vascular diseases (e.g., systemic lupus erythematosus); **inflammatory bowel diseases** (e.g., ulcerative colitis)
- Lymphocytosis
 - Accompanies monocytosis in many disorders associated with chronic immunological stimulation (e.g., tuberculosis, brucellosis); viral infections (e.g., hepatitis A, cytomegalovirus, Epstein-Barr virus); Bordetella pertussis infection

Morphology



Neutrophils containing coarse purple cytoplasmic granules (toxic granulations) and blue cytoplasmic patches of dilated endoplasmic reticulum (Döhle bodies)

Reading assignment -Acute Nonspecific 10/23/2016 Lymphadementis